<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26016784</article-id><article-id pub-id-type="pmc">4523283</article-id><article-id pub-id-type="doi">10.5935/abc.20150050</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Association between LDL-C, Non HDL-C, and Apolipoprotein B Levels with
Coronary Plaque Regression</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Masson</surname><given-names>Walter</given-names></name><xref ref-type="aff" rid="aff01">1</xref><xref ref-type="aff" rid="aff02">2</xref></contrib><contrib contrib-type="author"><name><surname>Siniawski</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff01">1</xref><xref ref-type="aff" rid="aff02">2</xref></contrib><contrib contrib-type="author"><name><surname>Lobo</surname><given-names>Mart&#x000ed;n</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Molinero</surname><given-names>Graciela</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Giorgi</surname><given-names>Mariano</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Huer&#x000ed;n</surname><given-names>Melina</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><xref ref-type="corresp" rid="c01"/></contrib-group><aff id="aff01"><label>1</label>Consejo de Epidemiolog&#x000ed;a y Prevenci&#x000f3;n Cardiovascular de la
Sociedad Argentina de Cardiolog&#x000ed;a, Buenos Aires - Argentina</aff><aff id="aff02"><label>2</label>Hospital Italiano de Buenos Aires, Buenos Aires -
Argentina</aff><author-notes><corresp id="c01"><bold>Mailing Address: Walter Masson</bold>, Hospita Italiano de
Buenos Aires. Gascon 450, Ciudad Aut&#x000f3;noma de Buenos Aires. Postal Code 1416, Buenos
Aires &#x02013; Argentina. E-mail:
<email>walter.masson@hospitalitaliano.org.ar</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>7</month><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>7</month><year>2015</year></pub-date><volume>105</volume><issue>1</issue><fpage>11</fpage><lpage>19</lpage><history><date date-type="received"><day>29</day><month>10</month><year>2014</year></date><date date-type="rev-recd"><day>09</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>18</day><month>3</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution NonCommercial License which permits unrestricted noncommercial
use, distribution, and reproduction in any medium provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Previous reports have inferred a linear relationship between LDL-C and changes in
coronary plaque volume (CPV) measured by intravascular ultrasound. However, these
publications included a small number of studies and did not explore other lipid
markers.</p></sec><sec><title>Objective</title><p>To assess the association between changes in lipid markers and regression of CPV
using published data.</p></sec><sec><title>Methods</title><p>We collected data from the control, placebo and intervention arms in studies that
compared the effect of lipidlowering treatments on CPV, and from the placebo and
control arms in studies that tested drugs that did not affect lipids. Baseline and
final measurements of plaque volume, expressed in mm<sup>3</sup>, were extracted
and the percentage changes after the interventions were calculated. Performing
three linear regression analyses, we assessed the relationship between percentage
and absolute changes in lipid markers and percentage variations in CPV.</p></sec><sec><title>Results</title><p>Twenty-seven studies were selected. Correlations between percentage changes in
LDL-C, non-HDL-C, and apolipoprotein B (ApoB) and percentage changes in CPV were
moderate (r = 0.48, r = 0.47, and r = 0.44, respectively). Correlations between
absolute differences in LDL-C, non&#x02011;HDL-C, and ApoB with percentage differences in
CPV were stronger (r = 0.57, r = 0.52, and r = 0.79). The linear regression model
showed a statistically significant association between a reduction in lipid
markers and regression of plaque volume.</p></sec><sec><title>Conclusion</title><p>A significant association between changes in different atherogenic particles and
regression of CPV was observed. The absolute reduction in ApoB showed the
strongest correlation with coronary plaque regression.</p></sec></abstract><kwd-group><kwd>Cardiovascular Diseases</kwd><kwd>Atherosclerosis/physiopathology</kwd><kwd>Cholesterol, LDL</kwd><kwd>Apolipoprotein B/therapeutic use</kwd><kwd>Lipoproteins, LDL</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>In the last twenty years, strong evidence from clinical studies demonstrated that the
reduction of low-density lipoprotein cholesterol (LDL-C) with different lipid-lowering
drugs, mainly HMG-CoA reductase inhibitors (statins), is critical in decreasing the
incidence of coronary events <sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup>. Similarly, different studies showed an
association between LDL-C reduction and regression of coronary plaque measured by
intravascular ultrasound (IVUS)<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup>. A recent meta-regression study has shown
that pharmacologically induced regression of atherosclerotic plaque burden is associated
with clinically significant reduction of myocardial infarction and
revascularization<sup><xref rid="r05" ref-type="bibr">5</xref></sup>.</p><p>Previous reports inferred a linear association between LDL-C and changes in coronary
plaque volume (CPV) assessed by IVUS<sup><xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup>. However, these publications included a
small number of studies and did not explore the relationship with other lipid markers
like non&#x02013;high-density lipoprotein cholesterol (non-HDL-C) or apolipoprotein B (ApoB),
which in several reports were related more closely to the risk of vascular disease than
LDL-C itself<sup><xref rid="r08" ref-type="bibr">8</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup>.</p><p>In this context, the aim of our study was to assess the association between changes in
plasma levels of lipid markers (LDL-C, non-HDL-C, and ApoB) and the regression of
coronary atherosclerotic plaque measured by IVUS using published data.</p></sec><sec sec-type="methods"><title>Methods</title><p>Two reviewers independently searched the electronic databases PubMed/Medline, EMBASE and
Cochrane Clinical Trials using the following terms: "intravascular ultrasound", "IVUS",
"regression of atherosclerosis", and "statins". Studies were selected according to the
following criteria: a) trials that explored the effect of one or more different
lipid-lowering drugs (or different dosages) on the variation in CPV evaluated by IVUS
(total atheroma volume), b) at least three months of follow-up, and c)&#x000a0;availability of
plaque volume measurements expressed in mm<sup>3</sup>. In studies that tested drugs
that did not affect lipids, only the placebo and control arms were used. In these
circumstances, we did not consider the active arm due to potential bias related with
extra-lipid mechanisms that could affect plaque regression. Mean values were considered
for this analysis.</p><p>The quality of the studies was assessed with the Jadad scale. Potential publication
biases were assessed with the Begg&#x02019;s test.</p><p>Changes in lipid measurements (LDL-C, non-HDL-C, ApoB, and HDL-C) between baseline and
end of follow-up were calculated and expressed in percentages and absolute values
(mg/dL). We collected data from the control, placebo, and intervention arms in studies
that compared the effect of different lipid-lowering treatments, and only from the
placebo and control arms in studies that tested drugs that do not modify lipid levels.
Baseline and final measurements of the CPV (expressed in mm<sup>3</sup>) were extracted
and the percent changes were calculated using the formula: CPV Completion of Study - CPV
Baseline/ CPV Baseline x 100.</p><p>Several linear regression analyses were performed. In the first model, we analyzed the
relationship between percentage changes in LDL-C, non-HDL-C, and ApoB and percentage
changes in CPV, comparing the baseline and final measurements in the same arm. These
associations were adjusted for treatment time. In the second analysis, we assessed the
relationship between absolute differences in lipid levels and percentage differences in
CPV. For this analysis we calculated the absolute differences of the changes in lipid
levels and the percentage differences of the variation in CPV measurements (follow-up -
baseline values) between the intervention and control or placebo arms. Finally, we
explored the association between LDL-C, non-HDL-C, and ApoB levels achieved at the end
of follow-up (goal) and the percentage changes in CPV. To analyze the correlation, we
used Pearson&#x02019;s correlation coefficient. To interpret the data within a clinical context,
we tested associations between LDL-C, non-HDL-C, and ApoB levels below the goals
recommended by most current guidelines and changes in CVP (&#x0003c;&#x000a0;70, &#x0003c;&#x000a0;100, and
&#x0003c;&#x000a0;80 mg/dL, respectively).</p><p>Data analysis was performed using Stata 11.1 and Epidat&#x000a0;3.1. All statistical tests were
two sided and the statistical significance level alpha was set at 0.05 for the
analysis.</p></sec><sec sec-type="results"><title>Results</title><p>Two independent authors searched the literature looking for studies compatible with the
mentioned criteria. Of the 745 potential citations, 52 studies that evaluated any
therapy on the regression of coronary plaque measured by IVUS were selected. Twenty-five
studies were excluded due to the following main causes: absence of lipid values at the
end of follow-up, quantification of plaque regression by another method, follow-up
limitations, assessment of drugs not affecting lipids, or absence of a control/placebo
arm. Most studies were randomized (77%) and two-thirds of them showed acceptable quality
(3 or more points on the Jadad scale). We analyzed and discarded publication bias using
the Begg's test (p = 0.55). Since not all studies reported ApoB values, more patients
were included in the LDL-C and non-HDL-C analyses (4685) compared with the ApoB analysis
(3065). A flow diagram of the study&#x02019;s screening process is shown in <xref ref-type="fig" rid="f01">Figure 1</xref>. Most studies included patients with stable coronary heart
disease. Two studies included patients with acute coronary syndromes, one study included
individuals with diabetes and another included subjects with metabolic syndrome. In
studies involving patients with acute ischemic syndromes, IVUS measurement in the target
segment was determined in a non-percutaneous coronary angioplasty site.</p><fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow diagram of the study screening process</p></caption><graphic xlink:href="abc-105-01-0011-g01"/></fig><p>Follow-up ranged from 3 to 24 months. The main characteristics of the 27 studies
selected are shown in <xref ref-type="table" rid="t01">Table 1</xref>.</p><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><p>Studies included in the analysis (n = 4685)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
<bold>Study</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Intervention (mg/day)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>n</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Change in LDL-C (%)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Change in non- HDL-C (%)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Change in ApoB (%)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Change in coronary plaque volume (%)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Months of treatment exposure</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">REVERSAL<xref rid="r10" ref-type="bibr">10</xref></td><td align="center" rowspan="1" colspan="1">Atorvastatin 80</td><td align="center" rowspan="1" colspan="1">253</td><td align="center" rowspan="1" colspan="1">-46.3</td><td align="center" rowspan="1" colspan="1">-42.9</td><td align="center" rowspan="1" colspan="1">-39.1</td><td align="center" rowspan="1" colspan="1">-0.4</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td rowspan="1" colspan="1">REVERSAL<xref rid="r10" ref-type="bibr">10</xref></td><td align="center" rowspan="1" colspan="1">Pravastatin 40</td><td align="center" rowspan="1" colspan="1">249</td><td align="center" rowspan="1" colspan="1">-25.2</td><td align="center" rowspan="1" colspan="1">-24.7</td><td align="center" rowspan="1" colspan="1">-22</td><td align="center" rowspan="1" colspan="1">2.7</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td rowspan="1" colspan="1">ESTABLISH<xref rid="r11" ref-type="bibr">11</xref></td><td align="center" rowspan="1" colspan="1">Atorvastatin 20</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">-41.7</td><td align="center" rowspan="1" colspan="1">-35.4</td><td align="center" rowspan="1" colspan="1">-27.9</td><td align="center" rowspan="1" colspan="1">-13.1</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">ESTABLISH<xref rid="r11" ref-type="bibr">11</xref></td><td align="center" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">-0.7</td><td align="center" rowspan="1" colspan="1">-1.9</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">8.7</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">JAPAN-ACS<xref rid="r12" ref-type="bibr">12</xref></td><td align="center" rowspan="1" colspan="1">Pitavastatin 4</td><td align="center" rowspan="1" colspan="1">125</td><td align="center" rowspan="1" colspan="1">-36.2</td><td align="center" rowspan="1" colspan="1">-30.5</td><td align="center" rowspan="1" colspan="1">-27.6</td><td align="center" rowspan="1" colspan="1">-16.9</td><td align="center" rowspan="1" colspan="1">8-12</td></tr><tr><td rowspan="1" colspan="1">JAPAN-ACS<xref rid="r12" ref-type="bibr">12</xref></td><td align="center" rowspan="1" colspan="1">Atorvastatin 20</td><td align="center" rowspan="1" colspan="1">127</td><td align="center" rowspan="1" colspan="1">-35.8</td><td align="center" rowspan="1" colspan="1">-30.1</td><td align="center" rowspan="1" colspan="1">-27.6</td><td align="center" rowspan="1" colspan="1">-18.1</td><td align="center" rowspan="1" colspan="1">8-12</td></tr><tr><td rowspan="1" colspan="1">SATURN<xref rid="r13" ref-type="bibr">13</xref></td><td align="center" rowspan="1" colspan="1">Atorvastatin 80</td><td align="center" rowspan="1" colspan="1">519</td><td align="center" rowspan="1" colspan="1">-41.5</td><td align="center" rowspan="1" colspan="1">-35.9</td><td align="center" rowspan="1" colspan="1">-28.4</td><td align="center" rowspan="1" colspan="1">-4.0</td><td align="center" rowspan="1" colspan="1">26</td></tr><tr><td rowspan="1" colspan="1">SATURN<xref rid="r13" ref-type="bibr">13</xref></td><td align="center" rowspan="1" colspan="1">Rosuvastatin 40</td><td align="center" rowspan="1" colspan="1">520</td><td align="center" rowspan="1" colspan="1">-47.8</td><td align="center" rowspan="1" colspan="1">-40.2</td><td align="center" rowspan="1" colspan="1">-30.9</td><td align="center" rowspan="1" colspan="1">-5.8</td><td align="center" rowspan="1" colspan="1">26</td></tr><tr><td rowspan="1" colspan="1">Hong et al.<xref rid="r14" ref-type="bibr">14</xref></td><td align="center" rowspan="1" colspan="1">Rosuvastatin 20</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">-49</td><td align="center" rowspan="1" colspan="1">-44</td><td align="center" rowspan="1" colspan="1">-36</td><td align="center" rowspan="1" colspan="1">-2.7</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">Hong et al.<xref rid="r14" ref-type="bibr">14</xref></td><td align="center" rowspan="1" colspan="1">Atorvastatin 40</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">-40</td><td align="center" rowspan="1" colspan="1">-35.4</td><td align="center" rowspan="1" colspan="1">-34</td><td align="center" rowspan="1" colspan="1">-1.9</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">COSMOS<xref rid="r15" ref-type="bibr">15</xref></td><td align="center" rowspan="1" colspan="1">Rosuvastatin 2,5-20</td><td align="center" rowspan="1" colspan="1">215</td><td align="center" rowspan="1" colspan="1">-38.6</td><td align="center" rowspan="1" colspan="1">-36.7</td><td align="center" rowspan="1" colspan="1">-31.3</td><td align="center" rowspan="1" colspan="1">-5.1</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td rowspan="1" colspan="1">ASTEROID<xref rid="r06" ref-type="bibr">6</xref></td><td align="center" rowspan="1" colspan="1">Rosuvastatin 40</td><td align="center" rowspan="1" colspan="1">346</td><td align="center" rowspan="1" colspan="1">-53.2</td><td align="center" rowspan="1" colspan="1">-47.2</td><td align="center" rowspan="1" colspan="1">-41.5</td><td align="center" rowspan="1" colspan="1">-6.7</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td rowspan="1" colspan="1">ARTMAP<xref rid="r16" ref-type="bibr">16</xref></td><td align="center" rowspan="1" colspan="1">Atorvastatin 10-20</td><td align="center" rowspan="1" colspan="1">143</td><td align="center" rowspan="1" colspan="1">-47</td><td align="center" rowspan="1" colspan="1">-43.4</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-3.9</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">ARTMAP<xref rid="r16" ref-type="bibr">16</xref></td><td align="center" rowspan="1" colspan="1">Rosuvastatin 20</td><td align="center" rowspan="1" colspan="1">128</td><td align="center" rowspan="1" colspan="1">-49</td><td align="center" rowspan="1" colspan="1">-45.9</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-7.4</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">GAIN<xref rid="r17" ref-type="bibr">17</xref></td><td align="center" rowspan="1" colspan="1">Atorvastatin 20-80</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">-42</td><td align="center" rowspan="1" colspan="1">-41</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">2.5</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">GAIN<xref rid="r17" ref-type="bibr">17</xref></td><td align="center" rowspan="1" colspan="1">Usual care</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">-16</td><td align="center" rowspan="1" colspan="1">-15.9</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">11.8</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">Kawasaki et al.<xref rid="r18" ref-type="bibr">18</xref></td><td align="center" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">-1.9</td><td align="center" rowspan="1" colspan="1">-1.1</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">Kawasaki et al.<xref rid="r18" ref-type="bibr">18</xref></td><td align="center" rowspan="1" colspan="1">Pravastatin 20</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">-31.5</td><td align="center" rowspan="1" colspan="1">-28.6</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-0.9</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">Kawasaki et al.<xref rid="r18" ref-type="bibr">18</xref></td><td align="center" rowspan="1" colspan="1">Atorvastatin 20</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">-38.7</td><td align="center" rowspan="1" colspan="1">-39.2</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-2.4</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">Jensen et al.<xref rid="r19" ref-type="bibr">19</xref></td><td align="center" rowspan="1" colspan="1">Simvastatin 40</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">-46.3</td><td align="center" rowspan="1" colspan="1">-42.8</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-6.3</td><td align="center" rowspan="1" colspan="1">3-12</td></tr><tr><td rowspan="1" colspan="1">Jensen et al.<xref rid="r19" ref-type="bibr">19</xref></td><td align="center" rowspan="1" colspan="1">Diet</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">-2.4</td><td align="center" rowspan="1" colspan="1">-2.1</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-0.4</td><td align="center" rowspan="1" colspan="1">3-12</td></tr><tr><td rowspan="1" colspan="1">Han et al.<xref rid="r20" ref-type="bibr">20</xref></td><td align="center" rowspan="1" colspan="1">Rosuvastatin 20</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">-54.2</td><td align="center" rowspan="1" colspan="1">-44.6</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-8.5</td><td align="center" rowspan="1" colspan="1">9-12</td></tr><tr><td rowspan="1" colspan="1">Han et al.<xref rid="r20" ref-type="bibr">20</xref></td><td align="center" rowspan="1" colspan="1">Rosuvastatin 20/Ramipril 10</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">-47.2</td><td align="center" rowspan="1" colspan="1">-43.6</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-11.6</td><td align="center" rowspan="1" colspan="1">9-12</td></tr><tr><td rowspan="1" colspan="1">STRADIVARIUS<xref rid="r21" ref-type="bibr">21</xref></td><td align="center" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">341</td><td align="center" rowspan="1" colspan="1">-3.2</td><td align="center" rowspan="1" colspan="1">-3.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td rowspan="1" colspan="1">A-PLUS<xref rid="r22" ref-type="bibr">22</xref></td><td align="center" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">154</td><td align="center" rowspan="1" colspan="1">1.7</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">-4</td><td align="center" rowspan="1" colspan="1">-1.2</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td rowspan="1" colspan="1">AQUARIUS<xref rid="r23" ref-type="bibr">23</xref></td><td align="center" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">233</td><td align="center" rowspan="1" colspan="1">5.6</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-1.1</td><td align="center" rowspan="1" colspan="1">26</td></tr><tr><td rowspan="1" colspan="1">Tani et al.<xref rid="r24" ref-type="bibr">24</xref></td><td align="center" rowspan="1" colspan="1">Pravastatin 10-20</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">-11.3</td><td align="center" rowspan="1" colspan="1">-12.1</td><td align="center" rowspan="1" colspan="1">-6.4</td><td align="center" rowspan="1" colspan="1">-12.6</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">Nozue et al.<xref rid="r25" ref-type="bibr">25</xref></td><td align="center" rowspan="1" colspan="1">Pitavastatin 4</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">-41</td><td align="center" rowspan="1" colspan="1">-37.9</td><td align="center" rowspan="1" colspan="1">-33</td><td align="center" rowspan="1" colspan="1">-2.2</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">Nozue et al.<xref rid="r25" ref-type="bibr">25</xref></td><td align="center" rowspan="1" colspan="1">Pravastatin 20</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">-29</td><td align="center" rowspan="1" colspan="1">-26.4</td><td align="center" rowspan="1" colspan="1">-25.2</td><td align="center" rowspan="1" colspan="1">-1.4</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">Hirayama et al.<xref rid="r26" ref-type="bibr">26</xref></td><td align="center" rowspan="1" colspan="1">Atorvastatin 10-20</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">-36.3</td><td align="center" rowspan="1" colspan="1">-36.4</td><td align="center" rowspan="1" colspan="1">-28.4</td><td align="center" rowspan="1" colspan="1">-18.9</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td rowspan="1" colspan="1">HEAVEN <xref rid="r27" ref-type="bibr">27</xref></td><td align="center" rowspan="1" colspan="1">Atorvastatin 80/Ezetimibe 10</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">-28.6</td><td align="center" rowspan="1" colspan="1">-32.3</td><td align="center" rowspan="1" colspan="1">-5.8</td><td align="center" rowspan="1" colspan="1">-2.9</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">HEAVEN<xref rid="r27" ref-type="bibr">27</xref></td><td align="center" rowspan="1" colspan="1">Standard treatment</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">-1.9</td><td align="center" rowspan="1" colspan="1">-9.2</td><td align="center" rowspan="1" colspan="1">7.4</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">CART-2<xref rid="r28" ref-type="bibr">28</xref></td><td align="center" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">111</td><td align="center" rowspan="1" colspan="1">-6.9</td><td align="center" rowspan="1" colspan="1">-8.4</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-0.3</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">ENCORE II<xref rid="r29" ref-type="bibr">29</xref></td><td align="center" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">112</td><td align="center" rowspan="1" colspan="1">-11.8</td><td align="center" rowspan="1" colspan="1">-9.8</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-0.3</td><td align="center" rowspan="1" colspan="1">18-24</td></tr><tr><td rowspan="1" colspan="1">Nasu et al.<xref rid="r30" ref-type="bibr">30</xref></td><td align="center" rowspan="1" colspan="1">Fluvastatin 40</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">-32.3</td><td align="center" rowspan="1" colspan="1">-32.8</td><td align="center" rowspan="1" colspan="1">-27</td><td align="center" rowspan="1" colspan="1">-8.3</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">Nasu et al.<xref rid="r30" ref-type="bibr">30</xref></td><td align="center" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2.3</td><td align="center" rowspan="1" colspan="1">2.5</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">Yamada et al.<xref rid="r31" ref-type="bibr">31</xref></td><td align="center" rowspan="1" colspan="1">Atorvastatin 10-20</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">-32.5</td><td align="center" rowspan="1" colspan="1">-29.8</td><td align="center" rowspan="1" colspan="1">-27.6</td><td align="center" rowspan="1" colspan="1">-1.9</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">Yamada et al.<xref rid="r31" ref-type="bibr">31</xref></td><td align="center" rowspan="1" colspan="1">Usual care</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-1.6</td><td align="center" rowspan="1" colspan="1">-2.2</td><td align="center" rowspan="1" colspan="1">11.5</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">Tani et al.<xref rid="r32" ref-type="bibr">32</xref></td><td align="center" rowspan="1" colspan="1">Pravastatin 10-20</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">-14</td><td align="center" rowspan="1" colspan="1">-17.9</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-14</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">Tani et al.<xref rid="r32" ref-type="bibr">32</xref></td><td align="center" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">3.6</td><td align="center" rowspan="1" colspan="1">2.5</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">Yokoyama et al.<xref rid="r33" ref-type="bibr">33</xref></td><td align="center" rowspan="1" colspan="1">Atorvastatin 10</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">-34</td><td align="center" rowspan="1" colspan="1">-30.5</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-5.6</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">Yokoyama et al.<xref rid="r33" ref-type="bibr">33</xref></td><td align="center" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">-4.4</td><td align="center" rowspan="1" colspan="1">-5.2</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-3.5</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">Nakayama et al.<xref rid="r34" ref-type="bibr">34</xref></td><td align="center" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">-7.1</td><td align="center" rowspan="1" colspan="1">-4.6</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">2.8</td><td align="center" rowspan="1" colspan="1">6</td></tr></tbody></table></table-wrap><p>Correlations between percentage changes in LDL-C, non-HDL-C, and ApoB with percentage
changes in CPV were moderate (r = 0.47, p = 0.0013; r = 0.46, p = 0.0016; and r = 0.43,
p = 0.03, respectively), whereas correlations between absolute differences in LDL-C,
non-HDL-C, and ApoB with percentage differences in CPV were stronger (r = 0.57, p =
0.015; r = 0.52, p = 0.03; and r = 0.80, p = 0.017, respectively). Similarly, the
correlation between LDL-C / HDL-C ratio and regression of atherosclerosis was moderate
(r = 0.47, p = 0.001). However, the correlation between HDL-C and percentage changes in
CPV was poor (r = 0.24, p = 0.08).</p><p>The linear regression model showed a significant association between percentage changes
in LDL-C (p&#x000a0;=&#x000a0;0.002), non-HDL-C (p = 0.002), and ApoB (p = 0.04) with percentage changes
in CPV (<xref ref-type="fig" rid="f02">Figures 2</xref>, <xref ref-type="fig" rid="f03">3</xref>, and <xref ref-type="fig" rid="f04">4</xref>). These associations remained
significant even after adjustment for treatment time (p = 0.006, p = 0.002 and p = 0.035
for LDL-C, non-HDL-C, and ApoB, respectively). Also, a significant association between
percentage changes in LDL-C / HDL-C ratio with percentage changes in CPV (p = 0.002) was
demonstrated, but not with changes in HDL-C (p = 0.09). Similarly, significant
associations were found between absolute reductions in LDL-C (p = 0.02), non-HDL-C (p =
0.03), and ApoB (p = 0.02) with percentage differences in CPV changes between groups.
<xref ref-type="fig" rid="f05">Figure 5</xref> illustrates the association between
the absolute reduction in ApoB and the percentage regression in CPV.</p><fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Relationship between changes in LDL-C plasma levels and variation in coronary
plaque volume</p></caption><graphic xlink:href="abc-105-01-0011-g02"/></fig><fig id="f03" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Relationship between changes in non-HDL-C plasma levels and variation in coronary
plaque volume</p></caption><graphic xlink:href="abc-105-01-0011-g03"/></fig><fig id="f04" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Relationship between changes in apolipoprotein B plasma levels and variation in
coronary plaque volume</p></caption><graphic xlink:href="abc-105-01-0011-g04"/></fig><fig id="f05" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Relationship between the absolute difference in apolipoprotein B plasma levels and
the percentage difference of the variation in coronary plaque volume</p></caption><graphic xlink:href="abc-105-01-0011-g05"/></fig><p>The correlation between the LDL-C goal and percentage change in CPV was moderate (r =
0.48, p = 0.01). However, this association was significant and continuous up to LDL-C
levels close to 50 mg/dL (<xref ref-type="fig" rid="f06">Figure 6</xref>). Similarly,
the correlation between the non-HDL-C goal and percentage change in CPV was significant
(p = 0.01) and continuous up to non-HDL-C levels close to 80 mg/dL. Finally, we found an
almost significant association (p = 0.056) between ApoB goal and percentage change in
CPV in values close to 60 mg/dL.</p><fig id="f06" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Relationship between LDL-C levels achieved at the end of the follow-up (LDL-C
goal) and percentage changes in coronary plaque volume</p></caption><graphic xlink:href="abc-105-01-0011-g06"/></fig><p>In a combined analysis of all treatment types, a 10% decrease in LDL-C, non-HDL-C, or
ApoB was associated, respectively, with 2.7%, 2.9%, and 3% regressions in CPV.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The regression of atherosclerosis is a surrogate of cardiovascular disease, and has been
evaluated in research studies mainly by IVUS and carotid ultrasound. However, the
independent predictive value of these methods is not similar. A recent meta-analysis
found no significant association between LDL-C reduction and progression of
atherosclerosis estimated by carotid intima-media thickness<sup><xref rid="r35" ref-type="bibr">35</xref></sup>. Furthermore, regression or slowed progression of
carotid intima-media thickness induced by cardiovascular drug therapies do not reflect
reductions in cardiovascular events<sup><xref rid="r36" ref-type="bibr">36</xref></sup>.</p><p>In contrast, analyses that have included only a few studies have shown a significant
association between LDL-C reduction and regression of coronary plaque measured by
IVUS<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup>. Also, the association between the regression of coronary
atherosclerotic plaque measured by IVUS and the incidence of non-fatal cardiovascular
events has been demostrated<sup><xref rid="r05" ref-type="bibr">5</xref></sup>. In our
study, IVUS was chosen as the most robust method to detect plaque regression, and this
was the first time that plasma levels of non HDL-C and ApoB were added to the
analysis.</p><p>Large body of evidence supports a central role for LDL-C lowering in the prevention of
atherosclerotic cardiovascular disease. However, the new guideline on the treatment of
blood cholesterol to reduce atherosclerotic cardiovascular risk in adults discourages
the use of absolute values of LDL-C as a &#x0201c;goal&#x0201d; and makes virtually no reference to
other markers more specific of atherogenic lipid particles, such as non-HDL-C or
ApoB<sup><xref rid="r37" ref-type="bibr">37</xref></sup>.</p><p>In our study, we found no threshold level of lipid reduction (absolute or percentage)
associated with an interruption in plaque regression, suggesting that lower levels of
atherogenic particles are associated with greater regression of plaque. In our analysis,
we observed a significant, sustained, and continuous association between LDL-C,
non-HDL-C, and ApoB levels at the end of follow-up with changes in CPV, suggesting that
the respective goals of &#x0003c; 70, &#x0003c; 100, and &#x0003c;&#x000a0;80&#x000a0;mg/dL recommended by most
guidelines is appropriate.<sup><xref rid="r38" ref-type="bibr">38</xref>,<xref rid="r39" ref-type="bibr">39</xref></sup> This finding does not conceptually agree
with the latest guideline, which recommends that an approximate 50% reduction in LDL-C
level is adequate regardless of the LDL-C goal achieved<sup><xref rid="r40" ref-type="bibr">40</xref></sup>.</p><p>Another interesting finding to emphasize is that the regression of atherosclerosis in
our study was independent of the lipid-lowering therapy (statins) and the dose used.
When significant reductions in LDL-C, non-HDL-C, or ApoB were achieved, plaque
regression was observed with different doses of statins. This finding also contrasts
with the new guideline that recommends only intensive doses of rosuvastatin or
atorvastatin. Finally, the significant association between the LDL-C / HDL-C ratio and
regression of atherosclerosis indicates the importance of a balance between pro- and
anti-atherogenic particles on vascular remodeling.</p><p>Correlations between the percentage reduction in different lipid markers and the CPV
regression in our study were moderate, suggesting that the progression/regression of
coronary atherosclerosis is multicausal. The correlation between the absolute change in
ApoB and the percentage variation in plaque volume was higher, although this result
emerges with the inclusion of a very small number of studies. This finding is consistent
with the concept that ApoB level could be a better predictor of cardiovascular events
than the LDL-C level, since it reflects more accurately the number of atherogenic
particles<sup><xref rid="r09" ref-type="bibr">9</xref></sup>.</p><sec><title>Study limitations</title><p>Like all analyses of secondary data, there are many limitations related to the
heterogeneity of the populations included, number of subjects analyzed and
variability of follow-up. We found heterogeneity when we analyzed the L&#x02019;Abb&#x000e9; and
Galbraith plots, but not all studies could be analyzed, since the data required for
the analysis were not always published. We understand that whereas there may be
&#x0201c;statistical heterogeneity&#x0201d;, we have not seen a marked clinical heterogeneity. Then,
the fundamental objective of our work was to show the linear relationship between the
changes in lipid levels and regression of atherosclerotic plaque, and not force a
summary measure.</p><p>In previous analysis, C-reactive protein level was an important determinant of plaque
regression. Our study did not analyze this biomarker. Also, the percentage atheroma
volume (PAV) is a more stable measurement of the coronary plaque than the total
atheroma volume. However, we decided to choose the percentage change in total
atheroma volume as the end point because the PAV was only reported in 15 of the 27
studies included in this analysis. Finally, this analysis was performed with data
imported from the studies and not with individual patient data; therefore, the
results are not entirely accurate.</p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>We found in our analysis significant associations between changes in LDL-C, non-HDL-C,
and ApoB levels and regression of coronary plaque measured by IVUS. These results are
aligned with the concept &#x0201c;lower LDL-C is better&#x0201d; and expand this assumption to other
atherogenic lipid markers.</p></sec></body><back><fn-group><fn fn-type="con"><p>
<bold>Author contributions</bold>
</p><p>Conception and design of the research: Masson W, Siniawski D, Huer&#x000ed;n M. Acquisition
of data: Masson W, Lobo M, Molinero G, Huer&#x000ed;n M. Analysis and interpretation of the
data: Masson W, Siniawski D, Lobo M, Giorgi M, Huer&#x000ed;n M. Statistical analysis: Masson
W, Lobo M. Writing of the manuscript: Masson W, Siniawski D, Molinero G, Huer&#x000ed;n M.
Critical revision of the manuscript for intellectual content: Masson W, Siniawski D,
Lobo M, Molinero G, Giorgi M, Huer&#x000ed;n M. Supervision / as the major investigador:
Masson W.</p></fn><fn fn-type="conflict"><p>
<bold>Potential Conflict of Interest</bold>
</p><p>Dr. Giorgi reported receiving an educational grant from Pfizer and BMS.</p></fn><fn fn-type="supported-by"><p>
<bold>Sources of Funding</bold>
</p><p>There were no external funding sources for this study.</p></fn><fn fn-type="other"><p>
<bold>Study Association</bold>
</p><p>This study is not associated with any thesis or dissertation work.</p></fn></fn-group><ref-list><title>References</title><ref id="r01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baigent</surname><given-names>C</given-names></name><name><surname>Keech</surname><given-names>A</given-names></name><name><surname>Kearney</surname><given-names>PM</given-names></name><name><surname>Blackwell</surname><given-names>L</given-names></name><name><surname>Buck</surname><given-names>G</given-names></name><name><surname>Pollicino</surname><given-names>C</given-names></name><etal/><collab>Cholesterol Treatment Trialists' Collaborators</collab></person-group><article-title>Efficacy and safety of cholesterol-lowering treatment: prospective
meta-analysis of data from 90,056 participants in 14 randomised trials of
statins</article-title><source>Lancet</source><year>2005</year><volume>366</volume><issue>9493</issue><fpage>1267</fpage><lpage>1278</lpage><pub-id pub-id-type="pmid">16214597</pub-id></element-citation></ref><ref id="r02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>F</given-names></name><name><surname>Huffman</surname><given-names>MD</given-names></name><name><surname>Macedo</surname><given-names>AF</given-names></name><name><surname>Moore</surname><given-names>TH</given-names></name><name><surname>Burke</surname><given-names>M</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><etal/></person-group><article-title>Statins for the primary prevention of cardiovascular
disease</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><volume>1</volume><elocation-id/></element-citation></ref><ref id="r03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalanuria</surname><given-names>AA</given-names></name><name><surname>Nyquist</surname><given-names>P</given-names></name><name><surname>Ling</surname><given-names>G</given-names></name></person-group><article-title>The prevention and regression of atherosclerotic plaques: emerging
treatments</article-title><source>Vasc Health Risk Manag</source><year>2012</year><volume>8</volume><fpage>549</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">23049260</pub-id></element-citation></ref><ref id="r04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedi</surname><given-names>U</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Molnar</surname><given-names>J</given-names></name><name><surname>Khosla</surname><given-names>S</given-names></name><name><surname>Arora</surname><given-names>R</given-names></name></person-group><article-title>Effects of statins on progression of coronary artery disease as
measured by intravascular ultrasound</article-title><source>J Clin Hypertens (Greenwich)</source><year>2011</year><volume>13</volume><issue>7</issue><fpage>492</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">21762362</pub-id></element-citation></ref><ref id="r05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Ascenzo</surname><given-names>F</given-names></name><name><surname>Agostoni</surname><given-names>P</given-names></name><name><surname>Abbate</surname><given-names>A</given-names></name><name><surname>Castagno</surname><given-names>D</given-names></name><name><surname>Lipinski</surname><given-names>MJ</given-names></name><name><surname>Vetrovec</surname><given-names>GW</given-names></name></person-group><article-title>Atherosclerotic coronary plaque regression and the risk of adverse
cardiovascular events: a meta-regression of randomized clinical
trials</article-title><source>Atherosclerosis</source><year>2013</year><volume>226</volume><issue>1</issue><fpage>178</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">23206978</pub-id></element-citation></ref><ref id="r06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Sipahi</surname><given-names>I</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Raichlen</surname><given-names>JS</given-names></name><name><surname>Ballantyne</surname><given-names>CM</given-names></name><etal/><collab>ASTEROID Investigators</collab></person-group><article-title>Effect of very high-intensity statin therapy on regression of coronary
atherosclerosis: the ASTEROID trial</article-title><source>JAMA</source><year>2006</year><volume>295</volume><issue>13</issue><fpage>1556</fpage><lpage>1565</lpage><pub-id pub-id-type="pmid">16533939</pub-id></element-citation></ref><ref id="r07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Tardif</surname><given-names>JC</given-names></name><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Revkin</surname><given-names>JH</given-names></name><name><surname>Shear</surname><given-names>CL</given-names></name><name><surname>Duggan</surname><given-names>WT</given-names></name><etal/><collab>ILLUSTRATE Investigators</collab></person-group><article-title>Effect of torcetrapib on the progression of coronary
atherosclerosis</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><issue>13</issue><fpage>1304</fpage><lpage>1316</lpage><pub-id pub-id-type="pmid">17387129</pub-id></element-citation></ref><ref id="r08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boekholdt</surname><given-names>SM</given-names></name><name><surname>Arsenault</surname><given-names>BJ</given-names></name><name><surname>Mora</surname><given-names>S</given-names></name><name><surname>Pedersen</surname><given-names>TR</given-names></name><name><surname>LaRosa</surname><given-names>JC</given-names></name><name><surname>Nestel</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Non-HDL cholesterol is a better predictor of cardiovascular events in
patients treated with statins</article-title><source>JAMA</source><year>2012</year><volume>307</volume><issue>12</issue><fpage>1302</fpage><lpage>1309</lpage><pub-id pub-id-type="pmid">22453571</pub-id></element-citation></ref><ref id="r09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McQueen</surname><given-names>MJ</given-names></name><name><surname>Hawken</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ounpuu</surname><given-names>S</given-names></name><name><surname>Sniderman</surname><given-names>A</given-names></name><name><surname>Probstfield</surname><given-names>J</given-names></name><etal/><collab>INTERHEART study investigators</collab></person-group><article-title>Lipids, lipoproteins, and apolipoproteins as risk markers of
myocardial infarction in 52 countries (the INTERHEART study): a case-control
study; INTERHEART study investigators</article-title><source>Lancet</source><year>2008</year><volume>372</volume><issue>9634</issue><fpage>224</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">18640459</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Tuzcu</surname><given-names>EM</given-names></name><name><surname>Schoenhagen</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>BG</given-names></name><name><surname>Ganz</surname><given-names>P</given-names></name><name><surname>Vogel</surname><given-names>RA</given-names></name><etal/><collab>REVERSAL Investigators</collab></person-group><article-title>Effect of intensive compared with moderate lipid-lowering therapy on
progression of coronary atherosclerosis: a randomized controlled
trial</article-title><source>JAMA</source><year>2004</year><volume>291</volume><issue>9</issue><fpage>1071</fpage><lpage>1080</lpage><pub-id pub-id-type="pmid">14996776</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okazaki</surname><given-names>S</given-names></name><name><surname>Yokoyama</surname><given-names>T</given-names></name><name><surname>Miyauchi</surname><given-names>K</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Kurata</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><etal/></person-group><article-title>Early statin treatment in patients with acute coronary syndrome:
demonstration of the beneficial effect on atherosclerotic lesions by serial
volumetric intravascular ultrasound analysis during half a year after coronary
event: the ESTABLISH Study</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>9</issue><fpage>1061</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">15326073</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiro</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Morimoto</surname><given-names>T</given-names></name><name><surname>Miyauchi</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>Y</given-names></name><name><surname>Yamagishi</surname><given-names>M</given-names></name><etal/><collab>JAPAN-ACS Investigators</collab></person-group><article-title>Effect of intensive statin therapy on regression of coronary
atherosclerosis in patients with acute coronary syndrome: a multicenter randomized
trial evaluated by volumetric intravascular ultrasound using pitavastatin versus
atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in
acute coronary syndrome] study)</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>54</volume><issue>4</issue><fpage>293</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">19608026</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Ballantyne</surname><given-names>CM</given-names></name><name><surname>Barter</surname><given-names>PJ</given-names></name><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Erbel</surname><given-names>RM</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effect of two intensive statin regimens on progression of coronary
disease</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>22</issue><fpage>2078</fpage><lpage>2087</lpage><pub-id pub-id-type="pmid">22085316</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>YJ</given-names></name><name><surname>Jeong</surname><given-names>MH</given-names></name><name><surname>Hachinohe</surname><given-names>D</given-names></name><name><surname>Ahmed</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>YH</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Comparison of effects of rosuvastatin and atorvastatin on plaque
regression in Korean patients with untreated intermediate coronary
stenosis</article-title><source>Circ J</source><year>2011</year><volume>75</volume><issue>2</issue><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">21157106</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayama</surname><given-names>T</given-names></name><name><surname>Hiro</surname><given-names>T</given-names></name><name><surname>Yamagishi</surname><given-names>M</given-names></name><name><surname>Daida</surname><given-names>H</given-names></name><name><surname>Hirayama</surname><given-names>A</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><etal/></person-group><article-title>COSMOS Investigators.Effect of rosuvastatin on coronary atheroma in
stable coronary artery disease: multicenter coronary atherosclerosis study
measuring effects of rosuvastatin using intravascular ultrasound in Japanese
subjects (COSMOS)</article-title><source>Circ J</source><year>2009</year><volume>73</volume><issue>11</issue><fpage>2110</fpage><lpage>2117</lpage><pub-id pub-id-type="pmid">19801853</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CW</given-names></name><name><surname>Kang</surname><given-names>SJ</given-names></name><name><surname>Ahn</surname><given-names>JM</given-names></name><name><surname>Song</surname><given-names>HG</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10
mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP
trial)</article-title><source>Am J Cardiol</source><year>2012</year><volume>109</volume><issue>12</issue><fpage>1700</fpage><lpage>1704</lpage><pub-id pub-id-type="pmid">22440123</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schartl</surname><given-names>M</given-names></name><name><surname>Bocksch</surname><given-names>W</given-names></name><name><surname>Koschyk</surname><given-names>DH</given-names></name><name><surname>Voelker</surname><given-names>W</given-names></name><name><surname>Karsch</surname><given-names>KR</given-names></name><name><surname>Kreuzer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Use of intravascular ultrasound to compare effects of different
strategies of lipid-lowering therapy on plaque volume and composition in patients
with coronary artery disease</article-title><source>Circulation</source><year>2001</year><volume>104</volume><issue>4</issue><fpage>387</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">11468198</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>M</given-names></name><name><surname>Sano</surname><given-names>K</given-names></name><name><surname>Okubo</surname><given-names>M</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Murata</surname><given-names>I</given-names></name><etal/></person-group><article-title>Volumetric quantitative analysis of tissue characteristics of coronary
plaques after statin therapy using three-dimensional integrated backscatter
intravascular ultrasound</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>45</volume><issue>12</issue><fpage>1946</fpage><lpage>1953</lpage><pub-id pub-id-type="pmid">15963391</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>LO</given-names></name><name><surname>Thayssen</surname><given-names>P</given-names></name><name><surname>Pedersen</surname><given-names>KE</given-names></name><name><surname>Stender</surname><given-names>S</given-names></name><name><surname>Haghfelt</surname><given-names>T</given-names></name></person-group><article-title>Regression of coronary atherosclerosis by simvastatin: a serial
intravascular ultrasound study</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>3</issue><fpage>265</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">15238460</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>SH</given-names></name><name><surname>Chung</surname><given-names>WJ</given-names></name><name><surname>Kang</surname><given-names>WC</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>YM</given-names></name><name><surname>Shin</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Rosuvastatin combined with ramipril significantly reduced atheroma
volume by anti-inflammatory mechanism: comparative analysis with rosuvastatin
alone by intravascular ultrasound</article-title><source>Int J Cardiol</source><year>2012</year><volume>158</volume><issue>2</issue><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">21295363</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Wolski</surname><given-names>K</given-names></name><name><surname>Rod&#x000e9;s-Cabau</surname><given-names>J</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Deanfield</surname><given-names>JE</given-names></name><etal/><collab>STRADIVARIUS Investigators</collab></person-group><article-title>Effect of rimonabant on progression of atherosclerosis in patients
with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized
controlled trial</article-title><source>JAMA</source><year>2008</year><volume>299</volume><issue>13</issue><fpage>1547</fpage><lpage>1560</lpage><pub-id pub-id-type="pmid">18387931</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tardif</surname><given-names>JC</given-names></name><name><surname>Gr&#x000e9;goire</surname><given-names>J</given-names></name><etal/><collab>L'Allier PL.Anderson TJ.Bertrand O.Reeves FAvasimibe and Progression of
Lesions on UltraSound Investigators</collab></person-group><article-title>Effects of the acyl coenzyme A: cholesterolacyltransferase inhibitor
avasimibe on human atherosclerotic lesions</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>21</issue><fpage>3372</fpage><lpage>3377</lpage><pub-id pub-id-type="pmid">15533865</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Kastelein</surname><given-names>JJ</given-names></name><name><surname>Menon</surname><given-names>V</given-names></name><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Armbrecht</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of aliskiren on progression of coronary disease in patients
with prehypertension: the AQUARIUS randomized clinical trial</article-title><source>JAMA</source><year>2013</year><volume>310</volume><issue>11</issue><fpage>1135</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">23999933</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tani</surname><given-names>S</given-names></name><name><surname>Nagao</surname><given-names>K</given-names></name><name><surname>Anazawa</surname><given-names>T</given-names></name><name><surname>Kawamata</surname><given-names>H</given-names></name><name><surname>Furuya</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Coronary plaque regression and lifestyle modification in patients
treated with pravastatin. Assessment mainly by daily aerobic exercise and an
increase in the serum level of high-density lipoprotein
cholesterol</article-title><source>Circ J</source><year>2010</year><volume>74</volume><issue>5</issue><fpage>954</fpage><lpage>961</lpage><pub-id pub-id-type="pmid">20234098</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nozue</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Tohyama</surname><given-names>S</given-names></name><name><surname>Umezawa</surname><given-names>S</given-names></name><name><surname>Kunishima</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><etal/></person-group><article-title>Statin treatment for coronary artery plaque composition based on
intravascular ultrasound radiofrequency data analysis</article-title><source>Am Heart J</source><year>2012</year><volume>163</volume><issue>2</issue><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">22305836</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirayama</surname><given-names>A</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Takayama</surname><given-names>T</given-names></name><name><surname>Honye</surname><given-names>J</given-names></name><name><surname>Komatsu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Qualitative and quantitative changes in coronary plaque associated
with atorvastatin therapy</article-title><source>Circ J</source><year>2009</year><volume>73</volume><issue>4</issue><fpage>718</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">19225206</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovarnik</surname><given-names>T</given-names></name><name><surname>Mintz</surname><given-names>GS</given-names></name><name><surname>Skalicka</surname><given-names>H</given-names></name><name><surname>Kral</surname><given-names>A</given-names></name><name><surname>Horak</surname><given-names>J</given-names></name><name><surname>Skulec</surname><given-names>R</given-names></name><etal/></person-group><article-title>Virtual histology evaluation of atherosclerosis regression during
atorvastatin and ezetimibe administration: HEAVEN study</article-title><source>Circ J</source><year>2012</year><volume>76</volume><issue>1</issue><fpage>176</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">22076422</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tardif</surname><given-names>JC</given-names></name><name><surname>Gr&#x000e9;goire</surname><given-names>J</given-names></name><name><surname>L'Allier</surname><given-names>PL</given-names></name><name><surname>Ibrahim</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Reeves</surname><given-names>F</given-names></name><etal/><collab>CART-2 Investigators</collab></person-group><article-title>Effects of the antioxidant succinobucol (AGI-1067) on human
atherosclerosis in a randomized clinical trial</article-title><source>Atherosclerosis</source><year>2008</year><volume>197</volume><issue>1</issue><fpage>480</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">17214993</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000fc;scher</surname><given-names>TF</given-names></name><name><surname>Pieper</surname><given-names>M</given-names></name><name><surname>Tendera</surname><given-names>M</given-names></name><name><surname>Vrolix</surname><given-names>M</given-names></name><name><surname>Rutsch</surname><given-names>W</given-names></name><name><surname>van den Branden</surname><given-names>F</given-names></name><etal/></person-group><article-title>Randomized placebo-controlled study on the effect of nifedipine on
coronary endothelial function and plaque formation in patients with coronary
artery disease: the ENCORE II study</article-title><source>Eur Heart J</source><year>2009</year><volume>30</volume><issue>13</issue><fpage>1590</fpage><lpage>1597</lpage><pub-id pub-id-type="pmid">19474053</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasu</surname><given-names>K</given-names></name><name><surname>Tsuchikane</surname><given-names>E</given-names></name><name><surname>Katoh</surname><given-names>O</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Ehara</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of fluvastatin on progression of coronary atherosclerotic
plaque evaluated by virtual histology intravascular ultrasound</article-title><source>JACC Cardiovasc Interv</source><year>2009</year><volume>2</volume><issue>7</issue><fpage>689</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">19628194</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Azuma</surname><given-names>A</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><name><surname>Sawada</surname><given-names>T</given-names></name><name><surname>Matsubara</surname><given-names>H</given-names></name><collab>REACH Study Group</collab></person-group><article-title>Randomized evaluation of atorvastatin in patients with coronary heart
disease: a serial intravascular ultrasound study</article-title><source>Circ J</source><year>2007</year><volume>71</volume><issue>12</issue><fpage>1845</fpage><lpage>1850</lpage><pub-id pub-id-type="pmid">18037734</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tani</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>I</given-names></name><name><surname>Anazawa</surname><given-names>T</given-names></name><name><surname>Kawamata</surname><given-names>H</given-names></name><name><surname>Tachibana</surname><given-names>E</given-names></name><name><surname>Furukawa</surname><given-names>K</given-names></name><etal/><collab>Surugadai Atherosclerosis Regression Investigators</collab></person-group><article-title>Effect of pravastatin on malondialdehyde-modified low-density
lipoprotein levels and coronary plaque regression as determined by
three-dimensional intravascular ultrasound</article-title><source>Am J Cardiol</source><year>2005</year><volume>96</volume><issue>8</issue><fpage>1089</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">16214443</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>M</given-names></name><name><surname>Komiyama</surname><given-names>N</given-names></name><name><surname>Courtney</surname><given-names>BK</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Namikawa</surname><given-names>S</given-names></name><name><surname>Kuriyama</surname><given-names>N</given-names></name><etal/></person-group><article-title>Plasma low-density lipoprotein reduction and structural effects on
coronary atherosclerotic plaques by atorvastatin as clinically assessed with
intravascular ultrasound radio-frequency signal analysis: a randomized prospective
study</article-title><source>Am Heart J</source><year>2005</year><volume>150</volume><issue>2</issue><fpage>287</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">16086932</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Komiyama</surname><given-names>N</given-names></name><name><surname>Yokoyama</surname><given-names>M</given-names></name><name><surname>Namikawa</surname><given-names>S</given-names></name><name><surname>Kuroda</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pioglitazone induces regression of coronary atherosclerotic plaques in
patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized
prospective study using intravascular ultrasound</article-title><source>Int J Cardiol</source><year>2010</year><volume>138</volume><issue>2</issue><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">18817993</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>Effect of statin therapy on the progression of common carotid artery
intima-media thickness: an updated systematic review and meta-analysis of
randomized controlled trials</article-title><source>J Atheroscler Thromb</source><year>2013</year><volume>20</volume><issue>1</issue><fpage>108</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">23095240</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costanzo</surname><given-names>P</given-names></name><name><surname>Perrone-Filardi</surname><given-names>P</given-names></name><name><surname>Vassallo</surname><given-names>E</given-names></name><name><surname>Paolillo</surname><given-names>S</given-names></name><name><surname>Cesarano</surname><given-names>P</given-names></name><name><surname>Brevetti</surname><given-names>G</given-names></name><etal/></person-group><article-title>Does carotid intima-media thickness regression predict reduction of
cardiovascular events? A meta-analysis of 41 randomized trials</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>56</volume><issue>24</issue><fpage>2006</fpage><lpage>2020</lpage><pub-id pub-id-type="pmid">21126642</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>NJ</given-names></name><name><surname>Robinson</surname><given-names>JG</given-names></name><name><surname>Lichtenstein</surname><given-names>AH</given-names></name><name><surname>Bairey Merz</surname><given-names>CN</given-names></name><name><surname>Blum</surname><given-names>CB</given-names></name><name><surname>Eckel</surname><given-names>RH</given-names></name><etal/></person-group><article-title>ACC/AHA guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults. A report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>63</volume><issue>25</issue><issue-part>Pt B</issue-part><fpage>2889</fpage><lpage>2934</lpage><pub-id pub-id-type="pmid">24239923</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiner</surname><given-names>Z</given-names></name><name><surname>Catapano</surname><given-names>AL</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Graham</surname><given-names>I</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><name><surname>Wiklund</surname><given-names>O</given-names></name><etal/></person-group><article-title>ESC/EAS guidelines for the management of dyslipidaemias: the Task
Force for the management of dyslipidaemias of the European Society of Cardiology
(ESC) and the European Atherosclerosis Society (EAS)</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><issue>14</issue><fpage>1769</fpage><lpage>1818</lpage><pub-id pub-id-type="pmid">21712404</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Gr&#x000e9;goire</surname><given-names>J</given-names></name><name><surname>Hegele</surname><given-names>RA</given-names></name><name><surname>Couture</surname><given-names>P</given-names></name><name><surname>Mancini</surname><given-names>GB</given-names></name><name><surname>McPherson</surname><given-names>R</given-names></name><etal/></person-group><article-title>2012 Update of the Canadian Cardiovascular Society Guidelines for the
diagnosis and treatment of dyslipidemia for the prevention of cardiovascular
disease in the adult</article-title><source>Can J Cardiol</source><year>2013</year><volume>29</volume><issue>2</issue><fpage>151</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">23351925</pub-id></element-citation></ref><ref id="r40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>KK</given-names></name><name><surname>Kastelein</surname><given-names>JJ</given-names></name><name><surname>Boekholdt</surname><given-names>SM</given-names></name><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Khaw</surname><given-names>KT</given-names></name><name><surname>Ballantyne</surname><given-names>CM</given-names></name><etal/></person-group><article-title>The ACC/AHA 2013 guideline on the treatment of blood cholesterol to
reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and
the uncertain: a comparison with ESC/EAS guidelines for the management of
dyslipidaemias 2011</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><issue>15</issue><fpage>960</fpage><lpage>968</lpage><pub-id pub-id-type="pmid">24639424</pub-id></element-citation></ref></ref-list></back></article>